Occlutech Wins German Supreme Court Ruling Against AGA / St. Jude Medical

By Occlutech Gmbh, PRNE
Wednesday, May 11, 2011

JENA, Germany, May 12, 2011 - Occlutech GmbH, a leading European developer of minimally invasive
implants for the treatment of structural heart disease, today announced that
it has received a favourable court ruling from the German Supreme Court,
(BGH), in Karlsruhe, Gerrmany in patent litigation initiated by AGA Medical
Inc., now part of St. Jude Medical Inc.

In the ruling by the BGH, the court does not see any basis for AGA / St.
Jude's claim that the Occlutech ASD and PFO occluders violate any patent
brought forward in the litigation and declares earlier German ruling to the
contrary invalid. The German Supreme Court ruling is similar in many aspects
to the first instance ruling in the UK which was confirmed by the appeal
court in the UK in mid 2010. The UK ruling is final as the UK supreme court
did not allow an appeal requested by AGA. The favourable German ruling is
also similar to first instance, as well as appeal court decisions in The
, in The Netherlands, the last one obtained at the end of 2010 as well
as a district court ruling in Stockholm, Sweden obtained in March 2011.

Throughout the litigation, Occlutech's owners and partners have funded
work in maintaining and substantially strengthening Occlutech's own patent
position. Meanwhile, a full pipeline of new technologies and products have
been developed. In 2011 and 2012 Occlutech expects to launch additional
occluders for indications such as PDA and VSD in addition to second
generation ASD and PFO occluders. Also, an innovative LAA occluder, a new
generation of stent grafts and cardiac valve intervention technologies are
being developed.

Occlutech intends to initiate litigation for substantial damages against
AGA / St. Jude.

For further information please contact: Tor Peters, +49-3641-67-51-29, tor.peters at occlutech.com ; Katrin Biedermann, +49-3641-67-51-20, katrin.biedermann at occlutech.com

will not be displayed